Mechanistically, PD-L1 expression should not be interpreted analogously to oncogenic target detection (as for HER2 or EGFR), since the therapeutic action of anti-PD-1/PD-L1 antibodies occurs primarily at the immune synapse rather than through direct elimination of PD-L1-positive tumor cells. This evidence concerns the gene EGFR and neoplasm.